文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Pan-Cancer Analysis Based on Expression With Potential Value in Prognosis and Tumor Immunity in 33 Tumors.

作者信息

Zhang Yajing, Wang Senyu, Han Songtao, Feng Yangchun

机构信息

Clinical Laboratory Center, Cancer Hospital Affiliated to Xinjiang Medical University, Xinjiang, China.

Xinjiang Key Laboratory of Oncology, Cancer Hospital Affiliated to Xinjiang Medical University, Xinjiang, China.

出版信息

Front Oncol. 2022 Mar 14;12:844794. doi: 10.3389/fonc.2022.844794. eCollection 2022.


DOI:10.3389/fonc.2022.844794
PMID:35359375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8963997/
Abstract

BACKGROUND: Erythropoietin receptor (EPOR), a member of the cytokine class I receptor family, mediates erythropoietin (EPO)-induced erythroblast proliferation and differentiation, but its significance goes beyond that. The expression and prognosis of in cancer remain unclear. METHODS: This study intended to perform a pan-cancer analysis of by bioinformatics methods. Several databases such as GTEx, TCGA, CCLE, and others were used to explore the overall situation of expression, and the correlation of expression with prognosis, microRNAs (miRNAs), immune infiltration, tumor microenvironment, immune checkpoint genes, chemokines, tumor mutation burden (TMB), microsatellite instability (MSI), methyltransferases, and DNA mismatch repair (MMR) genes in 33 tumors was analyzed. In addition, we compared the promoter methylation levels of in cancer tissues with those in normal tissues and performed protein-protein interaction network, gene-disease network, and genetic alteration analyses of , and finally enrichment analysis of EPOR-interacting proteins, co-expressed genes, and differentially expressed genes. RESULTS: The TCGA database showed that expression was upregulated in BLCA, CHOL, HNSC, KIRC, LIHC, STAD, and THCA and downregulated in LUAD and LUSC. After combining the GTEx database, expression was found to be downregulated in 18 cancer tissues and upregulated in 6 cancer tissues. The CCLE database showed that expression was highest in LAML cell lines and lowest in HNSC cell lines. Survival analysis showed that high expression was positively correlated with OS in LUAD and PAAD and negatively correlated with OS in COAD, KIRC, and MESO. Moreover, had a good prognostic ability for COAD, LUAD, MESO, and PAAD and also influenced progression-free survival, disease-specific survival, disease-free survival, and progression-free interval in specific tumors. Further, was found to play a non-negligible role in tumor immunity, and a correlation of with miRNAs, TMB, MSI, and MMR genes and methyltransferases was confirmed to some extent. In addition, the enrichment analysis revealed that is involved in multiple cancer-related pathways. CONCLUSION: The general situation of expression in cancer provided a valuable clinical reference. may be target gene of hsa-miR-575, etc. A pan-cancer analysis of panoramic schema revealed that EPOR not only may play an important role in mediating EPO-induced erythroblast proliferation and differentiation but also has potential value in tumor immunity and is expected to be a prognostic marker for specific cancers.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/a78112453c1c/fonc-12-844794-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/cf8126f13411/fonc-12-844794-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/98457277ef5c/fonc-12-844794-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/9ad040efed8d/fonc-12-844794-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/5dc0c4b9f62a/fonc-12-844794-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/24b9b19fb7bd/fonc-12-844794-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/d14d0f122c83/fonc-12-844794-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/c854490db3eb/fonc-12-844794-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/5984eb1e9d52/fonc-12-844794-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/a3750c5333c4/fonc-12-844794-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/a6bdab565247/fonc-12-844794-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/a78112453c1c/fonc-12-844794-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/cf8126f13411/fonc-12-844794-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/98457277ef5c/fonc-12-844794-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/9ad040efed8d/fonc-12-844794-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/5dc0c4b9f62a/fonc-12-844794-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/24b9b19fb7bd/fonc-12-844794-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/d14d0f122c83/fonc-12-844794-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/c854490db3eb/fonc-12-844794-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/5984eb1e9d52/fonc-12-844794-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/a3750c5333c4/fonc-12-844794-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/a6bdab565247/fonc-12-844794-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/809e/8963997/a78112453c1c/fonc-12-844794-g011.jpg

相似文献

[1]
Pan-Cancer Analysis Based on Expression With Potential Value in Prognosis and Tumor Immunity in 33 Tumors.

Front Oncol. 2022-3-14

[2]
Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.

Comput Struct Biotechnol J. 2022-6-18

[3]
Pan-Cancer Analysis Revealed as a New Biomarker for Prognosis and Immunotherapy.

J Oncol. 2022-1-12

[4]
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.

Front Immunol. 2021

[5]
Identifies microtubule-binding protein as a novel cancer biomarker associated with ferroptosis and tumor microenvironment.

Comput Struct Biotechnol J. 2022-6-24

[6]
Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.

Sci Rep. 2024-10-15

[7]
[Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].

Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023-6-20

[8]
HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.

Biomed Res Int. 2022

[9]
CCND1 as a Prognostic and Diagnostic Biomarker and the Impact of Its Epigenetic Alterations on Cancer Survival.

Cureus. 2024-7-27

[10]
Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.

Front Oncol. 2022-6-3

引用本文的文献

[1]
Genetic Insight Into Dissecting the FODMAP Diet Frame and Liver Cancer: The Mediation Role of Efferocytosis and Trogocytosis.

Food Sci Nutr. 2025-8-29

[2]
Construction and validation of a prognostic model for glioma: an analysis based on mismatch repair-related genes and their correlation with clinicopathological features.

Transl Cancer Res. 2025-5-30

[3]
Mechanistic Insights into Tumorigenesis from Serum Proteins.

medRxiv. 2025-6-5

[4]
Erythroid Cells as Full Participants in the Tumor Microenvironment.

Int J Mol Sci. 2023-10-13

[5]
Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.

Eur J Med Res. 2023-10-17

[6]
Differentially Expressed Genes Induced by Erythropoietin Receptor Overexpression in Rat Mammary Adenocarcinoma RAMA 37-28 Cells.

Int J Mol Sci. 2023-5-9

本文引用的文献

[1]
PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland.

Cancers (Basel). 2021-12-23

[2]
Deep-Tissue Fluorescence Imaging Study of Reactive Oxygen Species in a Tumor Microenvironment.

Anal Chem. 2022-1-11

[3]
DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis.

Annu Rev Pathol. 2022-1-24

[4]
Erythropoietin Non-hematopoietic Tissue Response and Regulation of Metabolism During Diet Induced Obesity.

Front Pharmacol. 2021-9-15

[5]
Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss.

Bone Res. 2021-9-13

[6]
The Role of PI3K/AKT and MAPK Signaling Pathways in Erythropoietin Signalization.

Int J Mol Sci. 2021-7-19

[7]
STAT5 as a Key Protein of Erythropoietin Signalization.

Int J Mol Sci. 2021-7-1

[8]
The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise.

Pflugers Arch. 2021-8

[9]
CHBP induces stronger immunosuppressive CD127 M-MDSC via erythropoietin receptor.

Cell Death Dis. 2021-2-12

[10]
New insights into erythropoietin and erythropoietin receptor in laryngeal cancer tissue.

Medicine (Baltimore). 2021-1-22

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索